Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00573573|
Recruitment Status : Unknown
Verified March 2009 by GAAD Medical Research Institute Inc..
Recruitment status was: Active, not recruiting
First Posted : December 14, 2007
Last Update Posted : March 24, 2009
|Condition or disease||Intervention/treatment||Phase|
|Hyperparathyroidism||Radiation: Far Infrared Radiation||Phase 1|
Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.
We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.|
|Study Start Date :||January 2007|
|Estimated Primary Completion Date :||March 2009|
|Estimated Study Completion Date :||July 2009|
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
- The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism. [ Time Frame: 2 years ]
- Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00573573
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Study Director:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|
|Study Chair:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|